You are here

Engineered proteins from transgenic animals

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM090626-01
Agency Tracking Number: GM090626
Amount: $172,499.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIGMS
Solicitation Number: PHS2010-2
Timeline
Solicitation Year: 2010
Award Year: 2010
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
5980 Horton Street Suite 405
EMERYVILLE, CA 94608
United States
DUNS: 827377933
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ROBERT ETCHES
 () -
Business Contact
 ROBERT ETCHES
Phone: (650) 430-3906
Email: RobEtches@CrystalBioscience.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Approximately 25% of the products being developed by the biotechnology industry are antibodies and many of these antibodies are directed to epitopes on human cells and tissues. We are proposing a novel concept for the production of antibodies with therapeutic potential that is based on recent advances in protein-protein interactions and recent developments in transgenic technology. Execution of this concept will obviate many of the expensive and time consuming modifications that are frequently required after potentially therapeutic monoclonal antibodies are identified in order to optimize their pharmacological properties and to make them amenable to large scale production. By combining recent data derived from in vitro studies with the nascent understanding of genomics, we will extend the range of epitopes that can be accessed and, therefore, extend the range of potentially therapeutic antibodies PUBLIC HEALTH RELEVANCE: During the past 15 years, more than 20 therapeutic antibodies have been developed to treat human disease, particularly in the fields of automimmunity and cancer. We have proposed a novel method to obtain potentially therapeutic antibodies that will recognize targets that cannot be obtained from conventional sources. In addition, the technology will engineer antibodies that have improved pharmacological attributes and better manufacturing properties. This technology will provide a cost-effective route to increasing the range of therapeutic candidates for the treatment of human disease.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government